

Screening for Sickle Cell Disease in Newborns

Population	All Newborns
Recommendation	Screen for Sickle Cell Disease
	Grade: A

Screening Tests	Screening for sickle cell disease in newborns is mandated in all 50 states and the District of Columbia. In most states, one of these tests is used for the initial screening: • thin-layer isoelectric focusing (IEF) • high performance liquid chromatography (HPLC) Both IEF and HPLC have extremely high sensitivity and specificity for sickle cell anemia.
Timing of Screening	All newborns should undergo screening regardless of birth setting. Birth attendants should make arrangements for samples to be obtained. The first clinician to see the infant at an office visit should verify screening results. Confirmatory testing should occur no later than 2 months of age.
Treatment	 Infants with sickle cell anemia should receive: prophylactic penicillin starting by age 2 months pneumococcal immunizations at recommended intervals
Other Relevant Recommendations from the USPSTF	Additional USPSTF recommendations regarding screening tests for newborns can be accessed at http://www.ahrq.gov/clinic/cps3dix.htm#pediatric

For the full recommendation statement on Screening for Sickle Cell Disease in Newborns and supporting documents please go to http://www.preventiveservices.ahrq.gov.

AHRQ Publication No. 07-05104-EF-3. August 2007.